Drug Profile
Onalespib - Astex Pharmaceuticals
Alternative Names: AT-13387; AT-13387XLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astex Therapeutics
- Developer Astex Pharmaceuticals; National Cancer Institute (USA)
- Class Antineoplastics; Benzamides; Isoindoles; Ketones; Piperazines; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- No development reported Gastrointestinal stromal tumours; Malignant melanoma; Prostate cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Triple negative Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 15 Aug 2020 National Cancer Institute completes a phase I trial in Solid tumours (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (NCT02503709)